abstract: PURPOSE: To investigate @entity13020 and @entity7 ( @entity7 ) levels in the vitreous fluid of @entity1 with @entity6 ( @entity6 ) and to examine their correlation with @entity6 activity. METHODS: Vitreous samples from 45 eyes with @entity6 and 28 eyes with @entity1020 were collected. Active @entity6 was present in 24 @entity1 and inactive @entity6 in 21 @entity1 , according to @entity2479 . The @entity13020 and @entity7 level of vitreous fluid samples were measured by enzyme-linked immunosorbent assay. RESULTS: Comparison revealed that mean intravitreal levels of @entity13020 increased significantly in @entity2194 compared with control eyes (13.55 ng/mL vs. 1.57 ng/mL, P < 0.001). The mean @entity7 concentrations in the vitreous fluid of @entity1 with @entity6 were also higher than those in nondiabetic controls, with the values being 723.21 pg/mL and 20.81 pg/mL, respectively (P < 0.001). In addition, vitreous concentrations of @entity13020 and @entity7 were significantly higher in active @entity6 than in eyes with inactive @entity6 (P = 0.016 and P = 0.008, respectively). Furthermore, a significant positive correlation was detected between @entity13020 and @entity7 levels in the vitreous. CONCLUSION: Intravitreous levels of @entity13020 and @entity7 in @entity1 with @entity6 are increased and correlated mutually. @entity13020 may be an important player in the development of @entity6 and its activity in vitreous fluid can be biomarker of @entity6 .

title: CORRELATION OF INCREASED INTRAVITREOUS @entity13020 WITH XXXX IN PROLIFERATIVE DIABETIC RETINOPATHY.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['proliferative diabetic retinopathy', 'PDR', 'diabetic retinopathy']

entities_list: @entity7 :: ('7422', 'Gene') :: ['vascular endothelial growth factor', 'VEGF']

entities_list: @entity2479 :: ('MESH:D012173', 'Disease') :: ['retinal neovascularization']

entities_list: @entity1020 :: ('MESH:D008268', 'Disease') :: ['nondiabetic macular disease']

answer: @entity7 :: (7422,Gene) :: ['VASCULAR ENDOTHELIAL GROWTH FACTOR']


abstract: PURPOSE: To investigate @entity13020 and @entity7 ( @entity7 ) levels in the vitreous fluid of @entity1 with @entity6 ( @entity6 ) and to examine their correlation with @entity6 activity. METHODS: Vitreous samples from 45 eyes with @entity6 and 28 eyes with @entity1020 were collected. Active @entity6 was present in 24 @entity1 and inactive @entity6 in 21 @entity1 , according to @entity2479 . The @entity13020 and @entity7 level of vitreous fluid samples were measured by enzyme-linked immunosorbent assay. RESULTS: Comparison revealed that mean intravitreal levels of @entity13020 increased significantly in @entity2194 compared with control eyes (13.55 ng/mL vs. 1.57 ng/mL, P < 0.001). The mean @entity7 concentrations in the vitreous fluid of @entity1 with @entity6 were also higher than those in nondiabetic controls, with the values being 723.21 pg/mL and 20.81 pg/mL, respectively (P < 0.001). In addition, vitreous concentrations of @entity13020 and @entity7 were significantly higher in active @entity6 than in eyes with inactive @entity6 (P = 0.016 and P = 0.008, respectively). Furthermore, a significant positive correlation was detected between @entity13020 and @entity7 levels in the vitreous. CONCLUSION: Intravitreous levels of @entity13020 and @entity7 in @entity1 with @entity6 are increased and correlated mutually. @entity13020 may be an important player in the development of @entity6 and its activity in vitreous fluid can be biomarker of @entity6 .

title: CORRELATION OF INCREASED INTRAVITREOUS XXXX WITH @entity7 IN PROLIFERATIVE DIABETIC RETINOPATHY.

answer: @entity13020 :: (89780,Gene) :: ['WNT3A']


abstract: BACKGROUND: Decompensated @entity712 ( @entity712 ) is associated with unacceptable morbidity and mortality risks. Recent implantable technology advancements allow frequent filling pressure monitoring and provide insight into @entity712 pathophysiology and a new tool for @entity712 management. METHODS: The CHAMPION trial is a prospective, multicenter, randomized, single-blind clinical trial testing the hypothesis that @entity712 management guided by frequently assessed @entity358 pressures is superior to traditional methods. A total of 550 subjects with New York Heart Association (NYHA) functional class III @entity712 were enrolled at 64 sites in the United States. All subjects received the CardioMEMS @entity712 sensor as a permanent @entity358 implant and were randomized to the treatment or the control group before discharge. The treatment group received traditional @entity712 management guided by hemodynamic information from the sensor. The control group received traditional @entity712 disease management. Safety endpoints include freedom from device/system-related complications and freedom from @entity712 at 6 months. The efficacy endpoint is a reduction in the rate of @entity712 -related hospitalizations in the treatment group versus the control group at 6 months. CONCLUSIONS: The CHAMPION trial will investigate the safety and clinical efficacy of the CardioMEMS hemodynamic monitoring system and may establish this management strategy as a new paradigm for the medical management of @entity1 with symptomatic @entity712 .

title: CHAMPION trial rationale and design: the long-term safety and clinical efficacy of a wireless XXXX pressure monitoring system.

entities_list: @entity712 :: ('MESH:D006333', 'Disease') :: ['HF', 'heart failure', 'HF sensor failure']

entities_list: @entity358 :: ('MESH:D008171', 'Disease') :: ['pulmonary artery']

answer: @entity358 :: (MESH:D008171,Disease) :: ['pulmonary artery']


abstract: UNASSIGNED: The essential oil from different parts of Datura metel L. were extracted using hydrodistillation and GC-MS was used to analyse the essential oil. The main components of flowers were @entity6178 (23.61%) and @entity37862 (15.84%). The main components of leaves were @entity6178 (18.84%) and @entity38091 (18.71%). @entity6178 (39.45%) and @entity38091 (31.32%) were the major components of petioles. @entity7609 (30.60%) and @entity57131 (21.56%) were the major components of seeds. The major ingredient of roots was @entity7609 (52.61%). The main ingredients of the stems were @entity7609 (38.38%) and @entity57131 (17.38%). All the different parts of essential oil were screened for @entity137 . The roots and stems showed the inhibitory effects against HepG-2 with IC50 levels of 613.88 and 341.12  mg/L. The leaves and roots showed the inhibitory effects against HeLa with IC50 levels of 267.76 and 348.35  mg/L. All the six parts have inhibitory effects against SGC-7901 cell lines.

title: Chemical composition and XXXX of the essential oil from different parts of Datura metel L.

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['cytotoxicity']

entities_list: @entity6178 :: ('CHEBI:17087', 'Chemical') :: ['Ketone', 'ketone']

entities_list: @entity57131 :: ('MESH:C007678', 'Chemical') :: ['ethyl linoleate']

entities_list: @entity37862 :: ('MESH:C007680', 'Chemical') :: ['ethyl palmitate']

entities_list: @entity7609 :: ('MESH:D019308', 'Chemical') :: ['palmitic acid', 'Palmitic acid']

answer: @entity137 :: (MESH:D064420,Disease) :: ['cytotoxicity']


abstract: AIM: Incisional @entity547 represent a late onset complication of any type of laparotomy, with a relatively high incidence, and reported in 2% to 11% of all laparotomies. MATERIAL AND METHODS: We performed a prospective longitudinal study that included a total number of 102 @entity1 . The following parameters were monitored: @entity1 history clinical findings, time of hospitalization, laboratory test results, types of surgery. Intra-abdominal pressure variations were measured using a specialized kit. RESULTS: Obesity was present in 69 of the @entity1 (67.64%). Mesh plasty was most frequently used (80.39%). The inset of the mesh was performed in onlay position (40.19%), retromuscular (29.98%) or complete defect substitution (11.76%). The correlation between the type of abdominal wall plasty, variations on the Borg @entity1353 scal and likewise the correlation between the VAS (visual analogue scale) pain scale and the abdominal wall plasty procedures proved to be highly statistically significant: p< 0.001. Furthermore, the intra-abdominal pressure varied with the type of abdominoplasty carried out, reviewing the tension free principle. The most important parameter was the intra-abdominal pressure recorded at the end of the abdominoplasty, which showed significant correlations with the tension free plasties (retromuscular mesh and substitution mesh). CONCLUSIONS: The tension free methods, reflected by the intra-abdominal pressure variation, were associated with a lower degree of @entity1353 , @entity282 and less hospitalization time. KEY WORDS: Borg scale, Incisional @entity547 , Intra-abdominal pressure, Onlay, Visual analogue scale.

title: The intraabdominal pressure A real indicator of the tension free principle during anterior wall repair procedure after incisional XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity282 :: ('MESH:D010149', 'Disease') :: ['low postoperative pain']

entities_list: @entity547 :: ('MESH:D006547', 'Disease') :: ['hernia', 'hernias']

answer: @entity547 :: (MESH:D006547,Disease) :: ['hernias']


abstract: BACKGROUND: Reliable blood and urine markers for transitional cell @entity150 ( @entity8214 ) do not currently exist. The aim of this prospective study was the serological and immunohistochemical evaluation of CA19.9 and @entity787 in @entity8214 and to assess the correlation with different @entity8214 stages. @entity1 AND METHODS: CA19.9 and @entity787 levels were prospectively determined in samples from 231 @entity1 with @entity8214 suspected @entity1494 , before transurethral @entity5 resection. Additionally, these serum parameters were determined in 11 @entity1 with initial metastatic @entity8214 . Immunohistochemical analysis on CA19.9 and @entity787 was performed in 83 @entity1 . RESULTS: Neither CA19.9 nor @entity787 levels were significantly elevated in @entity8214 @entity1 . @entity1 with muscle-invasive @entity8214 showed significantly higher levels of @entity787 (p = 0.008) and CA19.9 (p<0.001) compared to those with superficial @entity8214 . Significantly higher levels were also evident with increasing grade of @entity5 . Metastatic @entity8214 showed significantly elevated CA19.9 levels compared to muscle invasive @entity8214 as well as locally advanced ( @entity1803 /pT4/pN+) compared to localized @entity8214 (pT2/pN0). Immunohistochemical staining revealed a strong correlation between CA19.9 serum levels and staining intensity. CONCLUSION: @entity787 and CA19.9 are not useful markers in primary diagnosis of @entity8214 . However, in instances of elevated @entity787 and CA19.9 levels where @entity344 has been excluded, evidence of @entity8214 should be sought. If elevated @entity787 and CA19.9 are present in @entity8214 , serum levels correlate with @entity5 invasion and grade of @entity5 .

title: CA19.9 and @entity787 in transitional cell XXXX : serological and immunohistochemical findings.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'PATIENTS']

entities_list: @entity1494 :: ('MESH:D001745', 'Disease') :: ['bladder lesions']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'malignancy']

entities_list: @entity344 :: ('MESH:D005767', 'Disease') :: ['gastrointestinal malignancy']

entities_list: @entity150 :: ('MESH:D001749', 'Disease') :: ['carcinoma of the bladder']

answer: @entity150 :: (MESH:D001749,Disease) :: ['carcinoma of the bladder']


abstract: BACKGROUND: Reliable blood and urine markers for transitional cell @entity150 ( @entity8214 ) do not currently exist. The aim of this prospective study was the serological and immunohistochemical evaluation of CA19.9 and @entity787 in @entity8214 and to assess the correlation with different @entity8214 stages. @entity1 AND METHODS: CA19.9 and @entity787 levels were prospectively determined in samples from 231 @entity1 with @entity8214 suspected @entity1494 , before transurethral @entity5 resection. Additionally, these serum parameters were determined in 11 @entity1 with initial metastatic @entity8214 . Immunohistochemical analysis on CA19.9 and @entity787 was performed in 83 @entity1 . RESULTS: Neither CA19.9 nor @entity787 levels were significantly elevated in @entity8214 @entity1 . @entity1 with muscle-invasive @entity8214 showed significantly higher levels of @entity787 (p = 0.008) and CA19.9 (p<0.001) compared to those with superficial @entity8214 . Significantly higher levels were also evident with increasing grade of @entity5 . Metastatic @entity8214 showed significantly elevated CA19.9 levels compared to muscle invasive @entity8214 as well as locally advanced ( @entity1803 /pT4/pN+) compared to localized @entity8214 (pT2/pN0). Immunohistochemical staining revealed a strong correlation between CA19.9 serum levels and staining intensity. CONCLUSION: @entity787 and CA19.9 are not useful markers in primary diagnosis of @entity8214 . However, in instances of elevated @entity787 and CA19.9 levels where @entity344 has been excluded, evidence of @entity8214 should be sought. If elevated @entity787 and CA19.9 are present in @entity8214 , serum levels correlate with @entity5 invasion and grade of @entity5 .

title: CA19.9 and XXXX in transitional cell @entity150 : serological and immunohistochemical findings.

answer: @entity787 :: (1084,Gene) :: ['CEA']


abstract: PURPOSE: To report the radiological and clinical results of revision @entity572 ( @entity572 ) with femoral impaction bone grafting (IBG). METHODS: 4 @entity1 and 9 @entity1 (15 hips) aged 38 to 84 years underwent revision @entity572 with femoral IBG using Elite plus stems for aseptic loosening or @entity281 . RESULTS: The mean follow-up duration was 7.7 years. The Harris hip score improved from 61.7 to 83.7. There was no @entity158 in 11 hips and slight @entity158 in 4. The mean subsidence was 5.7 mm. The mean change of alignment was 1.2 degrees. There was no radiological evidence of stem loosening. One stem was revised due to a peri-prosthetic fracture. Cortical healing was noted in 11 hips, and trabecular incorporation in 10. CONCLUSION: Although intra- and post-operative complications were not uncommon, femoral IBG is a safe procedure in carefully selected @entity1 and offers good medium-term results.

title: Revision XXXX with femoral impaction bone grafting.

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients', 'men']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['infection']

entities_list: @entity572 :: ('MESH:D006617', 'Disease') :: ['THA', 'total hip arthroplasty']

answer: @entity572 :: (MESH:D006617,Disease) :: ['total hip arthroplasty']


abstract: UNASSIGNED: This study was designed to investigate whether @entity7080 inhibitors (PPI, V-ATPase blocker) could increase the effect of cytotoxic agents in @entity43 (EOC). Expression of V-ATPase protein was evaluated in @entity1 with EOC using immunohistochemistry, and @entity1 survival was compared based on expression of V-ATPase mRNA from a TCGA data set. In vitro, EOC cell lines were treated with chemotherapeutic agents with or without V-ATPase siRNA or PPI ( @entity4546 ) pretreatment. Cell survival and apoptosis was assessed using @entity98 assay and ELISA, respectively. In vivo experiments were performed to confirm the synergistic effect with @entity4546 and @entity1311 on @entity5 growth in orthotopic and @entity1 -derived xenograft (PDX) @entity19 models. Expression of V-ATPase protein in @entity43 tissues was observed in 44 @entity1 (44/59, 74.6%). Higher expression of V-ATPase mRNA was associated with poorer overall survival in TCGA data. Inhibition of V-ATPase by siRNA or @entity4546 significantly increased @entity137 or apoptosis to @entity1311 in chemoresistant (HeyA8-MDR, SKOV3-TR) and @entity1358 cells (ES-2, RMG-1), but not in chemosensitive cells (HeyA8, SKOV3ip1). Moreover, the combination of @entity4546 and @entity1311 significantly decreased the total @entity5 weight compared with @entity1311 alone in a chemoresistant EOC animal model and a PDX model of @entity1358 . However, this finding was not observed in chemosensitive EOC animal models. These results show that @entity4546 pretreatment can increase the effect of chemotherapeutic agents in chemoresistant EOC and @entity1358 via @entity5 microenvironment.

title: XXXX inhibitors enhance the effects of cytotoxic agents in @entity43 .

entities_list: @entity43 :: ('MESH:D010051', 'Disease') :: ['chemoresistant epithelial ovarian cancer', 'ovarian cancer']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'reduction of the acidic tumor']

entities_list: @entity1311 :: ('MESH:D017239', 'Chemical') :: ['paclitaxel']

entities_list: @entity1358 :: ('MESH:D002292', 'Disease') :: ['clear cell carcinoma']

entities_list: @entity4546 :: ('MESH:D009853', 'Chemical') :: ['omeprazole']

answer: @entity7080 :: (495,Gene) :: ['Proton pump']


abstract: UNASSIGNED: This study was designed to investigate whether @entity7080 inhibitors (PPI, V-ATPase blocker) could increase the effect of cytotoxic agents in @entity43 (EOC). Expression of V-ATPase protein was evaluated in @entity1 with EOC using immunohistochemistry, and @entity1 survival was compared based on expression of V-ATPase mRNA from a TCGA data set. In vitro, EOC cell lines were treated with chemotherapeutic agents with or without V-ATPase siRNA or PPI ( @entity4546 ) pretreatment. Cell survival and apoptosis was assessed using @entity98 assay and ELISA, respectively. In vivo experiments were performed to confirm the synergistic effect with @entity4546 and @entity1311 on @entity5 growth in orthotopic and @entity1 -derived xenograft (PDX) @entity19 models. Expression of V-ATPase protein in @entity43 tissues was observed in 44 @entity1 (44/59, 74.6%). Higher expression of V-ATPase mRNA was associated with poorer overall survival in TCGA data. Inhibition of V-ATPase by siRNA or @entity4546 significantly increased @entity137 or apoptosis to @entity1311 in chemoresistant (HeyA8-MDR, SKOV3-TR) and @entity1358 cells (ES-2, RMG-1), but not in chemosensitive cells (HeyA8, SKOV3ip1). Moreover, the combination of @entity4546 and @entity1311 significantly decreased the total @entity5 weight compared with @entity1311 alone in a chemoresistant EOC animal model and a PDX model of @entity1358 . However, this finding was not observed in chemosensitive EOC animal models. These results show that @entity4546 pretreatment can increase the effect of chemotherapeutic agents in chemoresistant EOC and @entity1358 via @entity5 microenvironment.

title: @entity7080 inhibitors enhance the effects of cytotoxic agents in XXXX .

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['cytotoxicity']

answer: @entity43 :: (MESH:D010051,Disease) :: ['chemoresistant epithelial ovarian carcinoma']


abstract: BACKGROUND: Long-term effects of restrictive mitral annuloplasty (RMA), especially on hemodynamics and left ventricular (LV) function in @entity1 with functional @entity339 ( @entity339 ), have not been fully investigated. METHODS AND RESULTS: From 1999 to 2008, 44 @entity1 with @entity712 and functional @entity339 underwent RMA with stringent downsizing of the mitral annulus. Serial echocardiography was performed to evaluate LV function (reverse remodeling), estimated @entity551 (PAP) and mitral valve geometry at baseline and at discharge, and annually thereafter. Cardiac catheterization was performed at baseline, and at discharge to evaluate acute hemodynamic change. There were 3 early deaths, and the 5-year survival rate was 78    8%. In 41 survivors the clinical symptoms, stratified according to New York Heart Association class, significantly improved after surgery. Postoperative cardiac catheterization showed significant unloading for left ventricle, as well as improvement in LV systolic function. Serial echocardiography showed that improvements in LV function and systolic PAP were sustained in the majority of @entity1 . Multivariate Cox regression analysis identified preoperative @entity120 (systolic PAP>60 mm Hg) as the significant predictor for postoperative adverse @entity299 . CONCLUSIONS: RMA for functional @entity339 resulted in sustained improvement of hemodynamics and LV function over time. Additional studies are needed to define the negative impact of preoperative @entity120 in @entity1 with this condition.

title: Restrictive mitral annuloplasty for functional XXXX : acute hemodynamics and serial echocardiography.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity712 :: ('MESH:D006333', 'Disease') :: ['refractory heart failure']

entities_list: @entity339 :: ('MESH:D008944', 'Disease') :: ['MR', 'mitral regurgitation']

entities_list: @entity120 :: ('MESH:D006976', 'Disease') :: ['pulmonary hypertension']

entities_list: @entity299 :: ('MESH:D006331', 'Disease') :: ['cardiac events']

entities_list: @entity551 :: ('MESH:D007022', 'Disease') :: ['systolic pulmonary artery pressure']

answer: @entity339 :: (MESH:D008944,Disease) :: ['mitral regurgitation']


abstract: PURPOSE: To conduct ophthalmic, behavioral, electrophysiological, and genetic testing on two related Gordon setters presented for @entity227 and compare findings with those of nine related and unrelated Gordon setters. METHODS: All @entity235 underwent comprehensive ophthalmic examination. Maze testing was conducted under different light intensities. Rod and cone function was assessed electroretinographically. DNA samples were screened for five @entity235 retinal disease gene mutations. RESULTS: Ophthalmic examination was unremarkable in all @entity235 . There was no notable difference between day blind @entity235 and the reference population in scotopic and mesopic maze tests. Day blind @entity235 performed worse in the photopic maze with slower course completion time and more obstacle collisions. Electroretinography revealed extinguished cone function in day blind @entity235 and depressed rod responses in all but two reference @entity235 . One reference population @entity235 presented with @entity227 1 year after initial examination. Mutations that cause @entity3641 (in @entity73292 ) and @entity6391 (in @entity73293 and @entity73294 ) were not detected in any @entity235 tested, although five reference @entity235 were carriers of the mutation in C2orf71 that causes rod-cone degeneration 4 (rcd4) in Gordon setters and in polski owczarek nizinny @entity235 . CONCLUSIONS: This report describes a novel @entity989 in related Gordon setters that has clinical signs and vision testing results consistent with @entity3641 but electroretinographic results suggestive of @entity6391 . The majority of Gordon setters in this study had low rod responses on electroretinography but it is unclear whether this was indicative of @entity409 or normal for the breed. Longer-term observation of affected individuals is warranted.

title: Novel XXXX in related Gordon setters: a clinical, behavioral, electrophysiological, and genetic investigation.

entities_list: @entity227 :: ('MESH:D014786', 'Disease') :: ['day blindness']

entities_list: @entity409 :: ('MESH:D008107', 'Disease') :: ['rod dysfunction']

entities_list: @entity6391 :: ('MESH:D012174', 'Disease') :: ['cone-rod dystrophies', 'cone-rod dystrophy']

entities_list: @entity989 :: ('MESH:D012164', 'Disease') :: ['retinopathy']

entities_list: @entity3641 :: ('MESH:D003117', 'Disease') :: ['achromatopsia']

answer: @entity989 :: (MESH:D012164,Disease) :: ['retinopathy']


abstract: INTRODUCTION AND BACKGROUND: Surgical techniques for the treatment of @entity91 continue to evolve; however, there is still no accepted criterion standard. Until recently, the Alder Hey supraregional craniofacial department's experience was principally with combined wide-vertex suturectomy and biparietal barrel stave osteotomies. AIMS AND OBJECTIVES: To determine whether the technique of wide-vertex suturectomy and biparietal barrel stave osteotomies improves the cephalic index (CI) in scaphocephalic @entity1 and determine whether age at surgery influences outcomes. @entity1 AND METHODS: A literature review was undertaken to confirm recognized outcome measures. @entity1 who had surgery between 2000 and 2006 were enrolled in the audit. Prospective database review allowed preoperative and postoperative data collection at 6 weeks, 6 months, and 2 years. Statistical analysis was performed with Statview V.5.0.1 (Adept Scientific, Letchworth, UK). RESULTS: Of 73 @entity1 referred to the unit with @entity91 , 66 underwent surgery. Of these 66 @entity1 , 54 were @entity1 and 12 @entity1 . Mean age at surgery was 11.1 months, with a mode of 6 months and a median of 8 months (range, 4-56 mo). Mean change in CI from the preoperative value was significant at 6 weeks (P < 0.0001) and 6 months (P < 0.0001) after surgery. Early correction of @entity91 ( <= 9 mo) was associated with a normal CI at 6 weeks after surgery (P = 0.03). CONCLUSIONS: Wide-vertex suturectomy with biparietal barrel stave osteotomies are effective at increasing the CI in @entity1 with @entity91 . Early correction is associated with an improved CI in the short term, but long-term outcomes are unclear and require further follow-up studies.

title: Treatment of XXXX with combined vertex craniectomy and bilateral microbarrel staving.

entities_list: @entity91 :: ('MESH:D003398', 'Disease') :: ['scaphocephaly']

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'Patients', 'patients', 'PATIENTS', 'girls', 'boys']

answer: @entity91 :: (MESH:D003398,Disease) :: ['scaphocephaly']


abstract: The aim of this paper is to describe neurofeedback (NFB) treatment in @entity2438 ( @entity2438 ) @entity1 . There is no specific cure for @entity2438 and therapeutic guidelines are directed to improve the quality of life of @entity1 with @entity2438 by reducing the symptoms and by increasing their functioning. Neurofeedback is a computerized method based on tracking electrical activity of the brain (EEG) and giving a feedback about it. The method has been developed in neurophysiological labs of scientific institutes in USA and has been used very successfully for over last 20 years. It has proven its efficacy in practise, but also in scientific and clinical research. During 2010 and 2011 neurofeedback treatment was administered to 10 @entity1 (N=10, 7 males and 3 females) age range 4 to 7 years which have been diagnosed as @entity2438 (highly functional) with an unspecific impairment of speech development and trouble communicating. An evaluation of treatment was done according to estimation of changes in functioning (parents, teachers and therapists' ratings and all other experts that were monitoring the @entity1 before, during and after the treatment) and tracking of changes in electrophysiology. The results have shown most changes in behaviour (less aggressive, more cooperation, better communication), @entity1957 . According to the assessment of parents, teachers, therapists and other experts all @entity1 have accomplished a certain degree of improvement in the level of daily functioning. Our experiences in usage of neurofeedback in @entity2438 ( @entity2438 ) @entity1 confirmed previous data that this method can be applied to this category of @entity1 .

title: Neurofeedback application in the treatment of XXXX ( @entity2438 ).

entities_list: @entity1 :: ('9606', 'Species') :: ['child', 'children', 'patients', 'people']

entities_list: @entity1957 :: ('MESH:D019957', 'Disease') :: ['attention span and sensory motor skills']

entities_list: @entity2438 :: ('MESH:D001321', 'Disease') :: ['Autistic spectrum disorder', 'autism', 'autistic spectrum disorder', 'ASD']

answer: @entity2438 :: (MESH:D001321,Disease) :: ['autistic spectrum disorders']


abstract: The aim of this paper is to describe neurofeedback (NFB) treatment in @entity2438 ( @entity2438 ) @entity1 . There is no specific cure for @entity2438 and therapeutic guidelines are directed to improve the quality of life of @entity1 with @entity2438 by reducing the symptoms and by increasing their functioning. Neurofeedback is a computerized method based on tracking electrical activity of the brain (EEG) and giving a feedback about it. The method has been developed in neurophysiological labs of scientific institutes in USA and has been used very successfully for over last 20 years. It has proven its efficacy in practise, but also in scientific and clinical research. During 2010 and 2011 neurofeedback treatment was administered to 10 @entity1 (N=10, 7 males and 3 females) age range 4 to 7 years which have been diagnosed as @entity2438 (highly functional) with an unspecific impairment of speech development and trouble communicating. An evaluation of treatment was done according to estimation of changes in functioning (parents, teachers and therapists' ratings and all other experts that were monitoring the @entity1 before, during and after the treatment) and tracking of changes in electrophysiology. The results have shown most changes in behaviour (less aggressive, more cooperation, better communication), @entity1957 . According to the assessment of parents, teachers, therapists and other experts all @entity1 have accomplished a certain degree of improvement in the level of daily functioning. Our experiences in usage of neurofeedback in @entity2438 ( @entity2438 ) @entity1 confirmed previous data that this method can be applied to this category of @entity1 .

title: Neurofeedback application in the treatment of @entity2438 ( XXXX ).

answer: @entity2438 :: (MESH:D001321,Disease) :: ['ASD']


abstract: PURPOSE: Previous studies have suggested that postmenopausal @entity1 with @entity0 who present with wild-type @entity5320 may actually have similar or superior recurrence-free survival outcomes when given @entity440 in place of aromatase inhibitors (AIs). The present study established a @entity5320 multiple-genotype-based model to determine the optimal endocrine therapy for @entity1 harboring wild-type @entity5320 . METHODS: We created a Markov model to determine whether @entity440 or AIs maximized 5-year disease-free survival (DFS) for extensive metabolizer (EM) @entity1 using annual hazard ratio (HR) data from the @entity29906 -98 trial. We then replicated the model by evaluating 9-year event-free survival (EFS) using HR data from the ATAC trial. In addition, we employed two-way sensitivity analyses to explore the impact of HR of decreased-metabolizer (DM) and its frequency on survival by studying a range of estimates. RESULTS: The 5-year DFS of @entity440 -treated EM @entity1 was 83.3%, which is similar to that of genotypically unselected @entity1 who received an AI (83.7%). In the validation study, we further demonstrated that the 9-year EFS of @entity440 -treated EM @entity1 was 81.4%, which is higher than that of genotypically unselected @entity1 receiving @entity440 (78.4%) and similar to that of @entity1 receiving an AI (83.2%). Two-way sensitivity analyses demonstrated the robustness of the results. CONCLUSIONS: Our modeling analyses indicate that, among EM @entity1 , the DFS/EFS outcome of @entity1 receiving @entity440 is similar to that of @entity1 receiving an AI. Further prospective clinical trials are needed to evaluate the value of the @entity5320 genotype in the selection of endocrine therapy.

title: Tailoring adjuvant endocrine therapy for XXXX : a @entity5320 multiple-genotype-based modeling analysis and validation.

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients']

entities_list: @entity440 :: ('MESH:D013629', 'Chemical') :: ['tamoxifen']

entities_list: @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer']

answer: @entity0 :: (MESH:D001943,Disease) :: ['postmenopausal breast cancer']


abstract: PURPOSE: Previous studies have suggested that postmenopausal @entity1 with @entity0 who present with wild-type @entity5320 may actually have similar or superior recurrence-free survival outcomes when given @entity440 in place of aromatase inhibitors (AIs). The present study established a @entity5320 multiple-genotype-based model to determine the optimal endocrine therapy for @entity1 harboring wild-type @entity5320 . METHODS: We created a Markov model to determine whether @entity440 or AIs maximized 5-year disease-free survival (DFS) for extensive metabolizer (EM) @entity1 using annual hazard ratio (HR) data from the @entity29906 -98 trial. We then replicated the model by evaluating 9-year event-free survival (EFS) using HR data from the ATAC trial. In addition, we employed two-way sensitivity analyses to explore the impact of HR of decreased-metabolizer (DM) and its frequency on survival by studying a range of estimates. RESULTS: The 5-year DFS of @entity440 -treated EM @entity1 was 83.3%, which is similar to that of genotypically unselected @entity1 who received an AI (83.7%). In the validation study, we further demonstrated that the 9-year EFS of @entity440 -treated EM @entity1 was 81.4%, which is higher than that of genotypically unselected @entity1 receiving @entity440 (78.4%) and similar to that of @entity1 receiving an AI (83.2%). Two-way sensitivity analyses demonstrated the robustness of the results. CONCLUSIONS: Our modeling analyses indicate that, among EM @entity1 , the DFS/EFS outcome of @entity1 receiving @entity440 is similar to that of @entity1 receiving an AI. Further prospective clinical trials are needed to evaluate the value of the @entity5320 genotype in the selection of endocrine therapy.

title: Tailoring adjuvant endocrine therapy for @entity0 : a XXXX multiple-genotype-based modeling analysis and validation.

answer: @entity5320 :: (1565,Gene) :: ['CYP2D6']


abstract: UNASSIGNED: One important task in translational @entity5 research is the search for new prognostic biomarkers to improve survival prognosis for @entity1 . The use of high-throughput technologies allows simultaneous measurement of genome-wide gene expression or other genomic data for all @entity1 in a clinical trial. Penalized likelihood methods such as lasso regression can be applied to such high-dimensional data, where the number of (genomic) covariables is usually much larger than the sample size. There is a connection between the lasso and the Bayesian regression model with independent Laplace priors on the regression parameters, and understanding this connection has been useful for understanding the properties of lasso estimates in linear models (e.g. Park and Casella, ). In this paper, we study the lasso in the frequentist and Bayesian frameworks in the context of @entity797 models. For the Bayesian lasso we extend the approach by Lee et  al. (). In particular, we impose the lasso penalty only on the genome features, but not on relevant clinical covariates, to allow the mandatory inclusion of important established factors. We investigate the models in high- and low-dimensional simulation settings and in an application to @entity1072 .

title: Nonidentical twins: Comparison of frequentist and Bayesian lasso for XXXX models.

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer']

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity1072 :: ('MESH:D015451', 'Disease') :: ['chronic lymphocytic leukemia']

answer: @entity797 :: (1351,Gene) :: ['Cox']


abstract: The clinical and pathological associations of @entity99 in @entity1 who presented to the Royal Adelaide Hospital between January 1, 1968 and February 29, 1984 were reviewed retrospectively. Cases of @entity2835 were excluded. Of 59 @entity1 with @entity99 , clear associations with diseases were identified in 42 (71%) @entity1 . These were @entity370 (seven cases), @entity409 (12 cases), @entity253 (three cases), @entity378 (four cases), @entity4002 (three cases), other @entity281 (four cases), drug @entity56 (four cases) and @entity5 (five cases). Ten @entity1 had multiple associations and five other @entity1 presented without any clearly defined cause for @entity738 . Three of these latter @entity1 presented with an @entity221 , showed @entity382 and had abnormal results of liver function tests. These cases may represent the entity that is labeled "idiopathic @entity99 ". Two other @entity1 abused @entity167 . @entity738 were categorized morphologically as microgranulomas, macrogranulomas and lipogranulomas according to their size, organization and the presence of fat droplets. Microgranulomas were associated with diseases of short duration and less @entity409 . The presence of @entity738 did not confer any prognostic implication over and above that of the associated disease.

title: XXXX : a 15-year experience in the Royal Adelaide Hospital.

entities_list: @entity2835 :: ('MESH:D008105', 'Disease') :: ['primary biliary cirrhosis']

entities_list: @entity378 :: ('MESH:D014376', 'Disease') :: ['tuberculosis']

entities_list: @entity738 :: ('MESH:D006099', 'Disease') :: ['Granulomas', 'granulomas']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['neoplasms']

entities_list: @entity167 :: ('CHEBI:16236', 'Chemical') :: ['alcohol']

entities_list: @entity409 :: ('MESH:D008107', 'Disease') :: ['architectural disturbance of the liver parenchyma', 'chronic liver disease']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['infections']

entities_list: @entity253 :: ('MESH:D001660', 'Disease') :: ['biliary tract disease']

entities_list: @entity56 :: ('MESH:D004342', 'Disease') :: ['hypersensitivity']

entities_list: @entity382 :: ('MESH:D006529', 'Disease') :: ['hepatomegaly']

entities_list: @entity370 :: ('MESH:D012507', 'Disease') :: ['sarcoidosis']

entities_list: @entity99 :: ('MESH:D056486', 'Disease') :: ['hepatic granulomas', 'granulomatous hepatitis']

entities_list: @entity221 :: ('MESH:D005334', 'Disease') :: ['acute febrile illness']

answer: @entity99 :: (MESH:D056486,Disease) :: ['Hepatic granulomas']


abstract: OBJECTIVE: @entity16503 is a 5-alpha reductase inhibitor used to treat @entity1067 . @entity16503 lowers @entity1486 levels, which may lead to delays in the diagnosis and treatment of @entity263 ( @entity263 ). This study investigated @entity1 who underwent prostate biopsy (PBx) while receiving @entity16503 to investigate whether this agent affects the diagnosis and treatment of @entity263 . @entity1 AND METHODS: PBx was performed on six @entity1 receiving @entity16503 for > 3 months at our medical institutions between January 2010 and June 2013. No @entity1 underwent PBx before @entity16503 administration. We performed PBx both for @entity1 with high initial @entity1486 levels and for those with elevated @entity1486 levels with or without initial @entity1486 decline after @entity16503 administration. We also investigated clinicopathological findings. RESULTS: Mean age at the start of administration was 69.5    5.9 years (range, 59-77 years), mean duration of administration was 14.1    7.4 months (range, 4.0-23.5 months), mean prostate volume at the start of administration was 70.4    30.7 ml (range, 18.8-104.6 ml), and mean @entity1486 level at the start of administration was 7.7    3.3 ng/ml (range, 4.9-14.2 ng/ml). @entity1486 density was 0.098    0.045 ng/ml/cm3 (range, 0.042-0.181 ng/ml/cm3), and @entity1486 level at PBx was 5.4    2.7 ng/ml (range, 2.5-10.7 ng/ml). We detected three @entity263 @entity1 , and clinical stage in each case was cT1cN0M0. Radical retropubic prostatectomy was performed in two cases, and @entity342 -deprivation therapy was performed in one case. CONCLUSION: All @entity263 were detected in the early clinical stage. No delays in detection or treatment of @entity263 were seen in any cases. Careful observation of @entity1486 levels is simple and useful for detecting @entity263 in @entity1 under @entity16503 administration.

title: [CLINICOPATHOLOGICAL STUDY OF PROSTATE BIOPSY IN @entity1 RECEIVING XXXX FOR BENIGN PROSTATIC HYPERPLASIA].

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS']

entities_list: @entity263 :: ('MESH:D011471', 'Disease') :: ['prostate cancer', 'PCa']

entities_list: @entity1067 :: ('MESH:D011470', 'Disease') :: ['benign prostatic hyperplasia']

entities_list: @entity342 :: ('CHEBI:50113', 'Chemical') :: ['androgen']

entities_list: @entity16503 :: ('MESH:C108373', 'Chemical') :: ['Dutasteride', 'dutasteride']

entities_list: @entity1486 :: ('354', 'Gene') :: ['prostate-specific antigen (PSA)', 'PSA']

answer: @entity16503 :: (MESH:C108373,Chemical) :: ['DUTASTERIDE']


abstract: OBJECTIVE: @entity16503 is a 5-alpha reductase inhibitor used to treat @entity1067 . @entity16503 lowers @entity1486 levels, which may lead to delays in the diagnosis and treatment of @entity263 ( @entity263 ). This study investigated @entity1 who underwent prostate biopsy (PBx) while receiving @entity16503 to investigate whether this agent affects the diagnosis and treatment of @entity263 . @entity1 AND METHODS: PBx was performed on six @entity1 receiving @entity16503 for > 3 months at our medical institutions between January 2010 and June 2013. No @entity1 underwent PBx before @entity16503 administration. We performed PBx both for @entity1 with high initial @entity1486 levels and for those with elevated @entity1486 levels with or without initial @entity1486 decline after @entity16503 administration. We also investigated clinicopathological findings. RESULTS: Mean age at the start of administration was 69.5    5.9 years (range, 59-77 years), mean duration of administration was 14.1    7.4 months (range, 4.0-23.5 months), mean prostate volume at the start of administration was 70.4    30.7 ml (range, 18.8-104.6 ml), and mean @entity1486 level at the start of administration was 7.7    3.3 ng/ml (range, 4.9-14.2 ng/ml). @entity1486 density was 0.098    0.045 ng/ml/cm3 (range, 0.042-0.181 ng/ml/cm3), and @entity1486 level at PBx was 5.4    2.7 ng/ml (range, 2.5-10.7 ng/ml). We detected three @entity263 @entity1 , and clinical stage in each case was cT1cN0M0. Radical retropubic prostatectomy was performed in two cases, and @entity342 -deprivation therapy was performed in one case. CONCLUSION: All @entity263 were detected in the early clinical stage. No delays in detection or treatment of @entity263 were seen in any cases. Careful observation of @entity1486 levels is simple and useful for detecting @entity263 in @entity1 under @entity16503 administration.

title: [CLINICOPATHOLOGICAL STUDY OF PROSTATE BIOPSY IN XXXX RECEIVING @entity16503 FOR BENIGN PROSTATIC HYPERPLASIA].

answer: @entity1 :: (9606,Species) :: ['PATIENTS']


abstract: The @entity15131 ( @entity15131 ) is suggested to play a pivotal role in @entity161 ; however, the dissociation pattern of functional connectivity of @entity15131 subsystems remains uncharacterized in this disease. In this study, resting-state fMRI data were acquired from 55 @entity161 @entity1 and 53 matched healthy controls. @entity15131 connectivity was estimated from time courses of independent components. The lateral @entity15131 exhibited decreased connectivity with the unimodal sensorimotor cortex but increased connectivity with the heteromodal association areas in schizophrenics. The increased connectivity between the lateral @entity15131 and right control network was significantly correlated with negative and anergia factor scores in the @entity161 @entity1 . The anterior and posterior DMNs exhibited increased and decreased connectivity with the right control and lateral visual networks, respectively, in schizophrenics. The altered @entity15131 connectivity may underlie the @entity1833 , delusions, thought disturbances, and negative symptoms involved in @entity161 . Furthermore, @entity15131 connectivity patterns could be used to differentiate @entity1 from controls with 76.9% accuracy. These findings may shed new light on the distinct role of @entity15131 subsystems in @entity161 , thereby furthering our understanding of the pathophysiology of @entity161 . Elucidating key disease-related @entity15131 subsystems is critical for identifying treatment targets and aiding in the clinical diagnosis and development of treatment strategies.

title: Evidence of a dissociation pattern in default mode subnetwork functional connectivity in XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity15131 :: ('MESH:C537734', 'Disease') :: ['default mode network', 'DMN']

entities_list: @entity161 :: ('MESH:D012559', 'Disease') :: ['schizophrenia', 'schizophrenic']

entities_list: @entity1833 :: ('MESH:D006212', 'Disease') :: ['hallucinations']

answer: @entity161 :: (MESH:D012559,Disease) :: ['schizophrenia']


abstract: Right ventricular volume measurements and hemodynamic studies were performed in 20 @entity1 after total correction of @entity215 . There were 6 @entity1 with an extracardiac conduit and Hancock xenograft (G-1), 8 with an outflow tract patch (G-2) and 6 without or with a minimal right ventriculotomy and repair of pulmonary valve (G-3). The age at the time of operation was over 3 years in each @entity1 and averaged 5 +/- 2 (mean +/- SD) years. Right ventricular systolic pressure averaged 81 +/- 22, 55 +/- 22 and 58 +/- 30 mmHg in @entity73295 , respectively. Right ventriculography showed no contraction of the right ventricular free wall at the @entity254 to the conduit and poor contraction around the @entity254 in G-1. The right ventricular enddiastolic volume index (RVEDVI) was 114 +/- 31, 155 +/- 57 and 115 +/- 28 ml/m2 in @entity73295 , respectively. The right ventricular ejection fraction (RVEF) was 0.42 +/- 0.11 in G-1, 0.53 +/- 0.04 in G-2 (p less than 0.05, vs G-1) and 0.57 +/- 0.04 in G-3 (p less than 0.02, vs G-1). @entity338 was evident in 17 @entity1 , and RVEDVI correlated well with degrees of @entity358 . Fourteen @entity1 in G-2 and G-3 were divided into G-A and G-B to evaluate right ventricular function with or without pressure overloading of the right ventricle. G-A consisted of 7 @entity1 with a right ventricular systolic pressure of more than 50 mmHg (74 +/- 26) and G-B of 7 @entity1 with a value less than 50 mmHg (39 +/- 4). There was no difference in RVEDVI and RVEF between G-A and G-B. RVEF was significantly lower in G-1 than G-A (p less than 0.02) and G-B (p less than 0.05). These results suggested that an extracardiac conduit with Hancock xenograft reduced the contraction of the right ventricular free wall and induced a depressed right ventricular pump function in @entity1 with a high right ventricular pressure.

title: Right ventricular function after extracardiac conduit repair for XXXX . A comparison among surgical approaches.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity215 :: ('MESH:D013771', 'Disease') :: ['tetralogy of Fallot']

entities_list: @entity254 :: ('MESH:C563598', 'Disease') :: ['anastomosis']

entities_list: @entity338 :: ('MESH:D011665', 'Disease') :: ['Pulmonary regurgitation']

entities_list: @entity358 :: ('MESH:D008171', 'Disease') :: ['pulmonary incompetence']

answer: @entity215 :: (MESH:D013771,Disease) :: ['tetralogy of Fallot']


abstract: OBJECTIVE: The aim of this study was to evaluate the effect of topical application of @entity560 over implant surface, placed immediately to the extraction, throughout histological and histomorphometric analysis of peri-implant tissue. MATERIAL AND METHODS: Six American foxhound @entity235 were used in the study. Mandibular premolar distal roots were extracted. Twenty-four immediate conical C1 implants (MIS, Barlev, Israel) were randomly assigned to the distal site on each site of the mandible in three groups: (Group CI) 12 @entity702 implants alone; (Test Group @entity6684 ) 12 @entity702 implants supplemented with @entity560 . Prior to implanting, test implants ( @entity6684 ) were submerged in @entity560 10% solution. No treatment was applied at control implants (CI). After 12  weeks, animals were sacrificed. Block sections were obtained and processed for mineralized ground sectioning. Bone-to-implant contact (Total BIC and BIC%), new bone formation (NBF), interthread bone (ITB), and histological linear measurements (HLM) were analyzed. RESULTS: At 12  weeks, all implants were clinically stable and histologically osseointegrated. BIC evaluation showed Total BIC mean and SD values for @entity6684 (48.96      2.14), CI (44.56      1.75) (P  <  0.05), BIC% @entity6684 (43.59      0.98), and CI (42.67      9.26) (P  >  0.05). For interthread bone formation, values were as follows: @entity6684 (15.21      3.87), CI (14.79      1.45) (P  >  0.05), no statistically differences. Regarding peri-implant new bone formation, no statistically differences could be found between the two groups @entity6684 (31.87      1.23), CI (27.18      2.38) (P  >  0.05). For linear measurements, test group ( @entity6684 ) showed statistically significant less @entity604 (CBL) @entity6684 (0.37      0.12)*, CI (1.26      0.8) (P  <  0.05), and @entity560 implants showed less lingual junctional epithelium @entity6684 (1.58      0.43)*, CI (2.18      0.48) (P  <  0.05). No differences were observed in the buccal mucosa. CONCLUSION: With the limitation of animal studies, topical application of @entity560 on dental implants could reduce crestal @entity604 and increase 10% more bone-to-implant contact at 12-week follow-up period.

title: Topical applications of XXXX on implant surface for bone-to-implant contact enhance: a pilot study in @entity235 part II.

entities_list: @entity604 :: ('MESH:D016301', 'Disease') :: ['bone loss', 'buccal crestal bone loss']

entities_list: @entity702 :: ('MESH:D014025', 'Chemical') :: ['titanium']

entities_list: @entity560 :: ('MESH:D014807', 'Chemical') :: ['vitamin D']

answer: @entity560 :: (MESH:D014807,Chemical) :: ['vitamin D']


abstract: OBJECTIVE: The aim of this study was to evaluate the effect of topical application of @entity560 over implant surface, placed immediately to the extraction, throughout histological and histomorphometric analysis of peri-implant tissue. MATERIAL AND METHODS: Six American foxhound @entity235 were used in the study. Mandibular premolar distal roots were extracted. Twenty-four immediate conical C1 implants (MIS, Barlev, Israel) were randomly assigned to the distal site on each site of the mandible in three groups: (Group CI) 12 @entity702 implants alone; (Test Group @entity6684 ) 12 @entity702 implants supplemented with @entity560 . Prior to implanting, test implants ( @entity6684 ) were submerged in @entity560 10% solution. No treatment was applied at control implants (CI). After 12  weeks, animals were sacrificed. Block sections were obtained and processed for mineralized ground sectioning. Bone-to-implant contact (Total BIC and BIC%), new bone formation (NBF), interthread bone (ITB), and histological linear measurements (HLM) were analyzed. RESULTS: At 12  weeks, all implants were clinically stable and histologically osseointegrated. BIC evaluation showed Total BIC mean and SD values for @entity6684 (48.96      2.14), CI (44.56      1.75) (P  <  0.05), BIC% @entity6684 (43.59      0.98), and CI (42.67      9.26) (P  >  0.05). For interthread bone formation, values were as follows: @entity6684 (15.21      3.87), CI (14.79      1.45) (P  >  0.05), no statistically differences. Regarding peri-implant new bone formation, no statistically differences could be found between the two groups @entity6684 (31.87      1.23), CI (27.18      2.38) (P  >  0.05). For linear measurements, test group ( @entity6684 ) showed statistically significant less @entity604 (CBL) @entity6684 (0.37      0.12)*, CI (1.26      0.8) (P  <  0.05), and @entity560 implants showed less lingual junctional epithelium @entity6684 (1.58      0.43)*, CI (2.18      0.48) (P  <  0.05). No differences were observed in the buccal mucosa. CONCLUSION: With the limitation of animal studies, topical application of @entity560 on dental implants could reduce crestal @entity604 and increase 10% more bone-to-implant contact at 12-week follow-up period.

title: Topical applications of @entity560 on implant surface for bone-to-implant contact enhance: a pilot study in XXXX part II.

answer: @entity235 :: (9615,Species) :: ['dogs']


abstract: INTRODUCTION: Proto-oncogene survivin is a member of the inhibitor of apoptosis (IAP) family of proteins. The presence of serous antibodies against survivin in @entity1 with @entity785 has been previously reported; however, there are few reports regarding the pathophysiological relationship between survivin and @entity785 . We herein investigated the expression and function of survivin in SSc @entity1 . METHODS: We performed immunohistochemistry analyses to determine the expression of @entity9846 , cIAP and survivin in @entity272 from @entity1 with SSc and non-SSc. The expression levels of survivin in peripheral blood mononuclear cells (PBMCs) obtained from SSc @entity1 and healthy controls were evaluated using RT-PCR and flow cytometry. Additionally, the function of survivin was verified with overexpression experiments using monocyte-derived dendritic cells (Mo-DCs). RESULTS: The expression patterns of both @entity9846 and cIAP were similar, while only the survivin expression differed between the SSc and non-SSc @entity272 . Survivin-overexpressing cells were detected in the SSc dermis frequently. The positive rate of survivin in SSc dermis (64.3  %, 9/14) was higher than that in non-SSc dermis (11.2  %, 1/9). Furthermore, survivin(+) cells expressed @entity4896 , one of the DC markers. Real-time PCR and FACS analyses revealed that the survivin-WT (wild type) expression levels in PBMCs, in particular @entity5750 (+) monocytes, from SSc @entity1 were higher than that from healthy controls. Additionally, the overexpression experiments showed that survivin-WT-overexpressing @entity4896 (+) Mo-DCs have the characteristics of promoting cell cycle progression and decreasing apoptotic cells. CONCLUSIONS: These findings suggest that dermal survivin(+) @entity4896 (+) cell infiltration may be a potential biomarker of SSc @entity272 . PBMCs and monocytes from SSc @entity1 also overexpressed survivin; therefore, dermal survivin(+) DC may be derived from peripheral blood monocytes. Additionally, survivin may be involved in dermal @entity4896 (+) DC proliferation through cell cycle activation and resistance to apoptosis. Survivin may be an important molecule for the pathogenesis of SSc.

title: @entity4896 (+) survivin(+) dendritic cell infiltration in dermal lesions of XXXX .

entities_list: @entity272 :: ('MESH:D012871', 'Disease') :: ['skin lesions']

entities_list: @entity785 :: ('MESH:D012595', 'Disease') :: ['systemic sclerosis']

answer: @entity785 :: (MESH:D012595,Disease) :: ['systemic sclerosis']


abstract: INTRODUCTION: Proto-oncogene survivin is a member of the inhibitor of apoptosis (IAP) family of proteins. The presence of serous antibodies against survivin in @entity1 with @entity785 has been previously reported; however, there are few reports regarding the pathophysiological relationship between survivin and @entity785 . We herein investigated the expression and function of survivin in SSc @entity1 . METHODS: We performed immunohistochemistry analyses to determine the expression of @entity9846 , cIAP and survivin in @entity272 from @entity1 with SSc and non-SSc. The expression levels of survivin in peripheral blood mononuclear cells (PBMCs) obtained from SSc @entity1 and healthy controls were evaluated using RT-PCR and flow cytometry. Additionally, the function of survivin was verified with overexpression experiments using monocyte-derived dendritic cells (Mo-DCs). RESULTS: The expression patterns of both @entity9846 and cIAP were similar, while only the survivin expression differed between the SSc and non-SSc @entity272 . Survivin-overexpressing cells were detected in the SSc dermis frequently. The positive rate of survivin in SSc dermis (64.3  %, 9/14) was higher than that in non-SSc dermis (11.2  %, 1/9). Furthermore, survivin(+) cells expressed @entity4896 , one of the DC markers. Real-time PCR and FACS analyses revealed that the survivin-WT (wild type) expression levels in PBMCs, in particular @entity5750 (+) monocytes, from SSc @entity1 were higher than that from healthy controls. Additionally, the overexpression experiments showed that survivin-WT-overexpressing @entity4896 (+) Mo-DCs have the characteristics of promoting cell cycle progression and decreasing apoptotic cells. CONCLUSIONS: These findings suggest that dermal survivin(+) @entity4896 (+) cell infiltration may be a potential biomarker of SSc @entity272 . PBMCs and monocytes from SSc @entity1 also overexpressed survivin; therefore, dermal survivin(+) DC may be derived from peripheral blood monocytes. Additionally, survivin may be involved in dermal @entity4896 (+) DC proliferation through cell cycle activation and resistance to apoptosis. Survivin may be an important molecule for the pathogenesis of SSc.

title: XXXX (+) survivin(+) dendritic cell infiltration in dermal lesions of @entity785 .

answer: @entity4896 :: (909,Gene) :: ['CD1a']


abstract: Free @entity1718 (FFA), @entity13286 (DG), and water content were measured in the right and left cerebral hemispheres of @entity35 with @entity2657 cryogenically induced to the right cerebral hemisphere. The effect of @entity619 pretreatment was also studied. Twenty-four hours after lesion, maximal @entity4 was attained concomitant with an accumulation of FFA (8.5-fold) and DG (2.9-fold). @entity1474 ( @entity5204 ), primarily @entity4600 , increased greatly in both lipid pools. In the contralateral hemisphere, only DG levels increased, especially those containing @entity9525 and @entity3899 , which increased by almost 50%. By 48 h, FFA had decreased 60%, whereas DG had attained sham levels. These changes occurred prior to @entity4 resolution. @entity619 decreased the degree of @entity4 and the accumulation of @entity5204 -containing DG by 30% in both hemispheres. There was a complete inhibition of FFA and @entity1426 accumulation in the lesioned side. These results suggest that @entity619 : (1) inhibits phospholipases A2 that, in turn, decrease membrane phospholipid breakdown; and (2) has a limited effect on the enzymatic systems involved in @entity5204 -DG accumulation. Hence, in experimentally induced @entity2657 , @entity5204 -containing DG, rather than FFA, may be related closely to the spreading of @entity4 fluid.

title: @entity619 effect on free fatty acid and diacylglycerol accumulation during experimentally induced XXXX .

entities_list: @entity2657 :: ('MESH:D001929', 'Disease') :: ['vasogenic brain edema', 'brain edema']

entities_list: @entity4600 :: ('CHEBI:28125', 'Chemical') :: ['docosahexaenoic acid']

entities_list: @entity9525 :: ('CHEBI:25629', 'Chemical') :: ['stearate']

entities_list: @entity1426 :: ('MESH:D016718', 'Chemical') :: ['arachidonic acid']

entities_list: @entity1474 :: ('MESH:D005231', 'Chemical') :: ['Polyunsaturated fatty acids']

entities_list: @entity619 :: ('MESH:D003907', 'Chemical') :: ['Dexamethasone', 'dexamethasone']

entities_list: @entity13286 :: ('MESH:D004075', 'Chemical') :: ['diacylglycerols']

entities_list: @entity3899 :: ('CHEBI:32395', 'Chemical') :: ['arachidonate']

entities_list: @entity1718 :: ('MESH:D005227', 'Chemical') :: ['fatty acids']

answer: @entity2657 :: (MESH:D001929,Disease) :: ['vasogenic brain edema']


abstract: Free @entity1718 (FFA), @entity13286 (DG), and water content were measured in the right and left cerebral hemispheres of @entity35 with @entity2657 cryogenically induced to the right cerebral hemisphere. The effect of @entity619 pretreatment was also studied. Twenty-four hours after lesion, maximal @entity4 was attained concomitant with an accumulation of FFA (8.5-fold) and DG (2.9-fold). @entity1474 ( @entity5204 ), primarily @entity4600 , increased greatly in both lipid pools. In the contralateral hemisphere, only DG levels increased, especially those containing @entity9525 and @entity3899 , which increased by almost 50%. By 48 h, FFA had decreased 60%, whereas DG had attained sham levels. These changes occurred prior to @entity4 resolution. @entity619 decreased the degree of @entity4 and the accumulation of @entity5204 -containing DG by 30% in both hemispheres. There was a complete inhibition of FFA and @entity1426 accumulation in the lesioned side. These results suggest that @entity619 : (1) inhibits phospholipases A2 that, in turn, decrease membrane phospholipid breakdown; and (2) has a limited effect on the enzymatic systems involved in @entity5204 -DG accumulation. Hence, in experimentally induced @entity2657 , @entity5204 -containing DG, rather than FFA, may be related closely to the spreading of @entity4 fluid.

title: XXXX effect on free fatty acid and diacylglycerol accumulation during experimentally induced @entity2657 .

answer: @entity619 :: (MESH:D003907,Chemical) :: ['Dexamethasone']


abstract: We present our 12-year experience with surgical treatment of @entity439 of the thoracic aorta in a high-risk @entity1 population. Of 52 @entity1 with @entity439 , 36 @entity1 , aged 19 to 80 years, had operation. In 24 of the 36, there were three or more associated major disease processes, such as chronic @entity3617 , @entity101 @entity65 , @entity886 , @entity66 , @entity1028 , and @entity453 . Eight @entity1 with acute type A (ascending aorta) and seven with acute type B (descending aorta) @entity439 had emergency repair, with survival in four and seven, respectively. All @entity1 with chronic type A or B @entity439 had elective repair, and all @entity1 with acute or chronic type @entity439 had surgical treatment. Four @entity1 with acute type A and two with acute type B @entity439 had elective operation, with survival in three and one, respectively. Nine @entity1 with chronic type A and six with chronic type B @entity439 had elective operation, and all survived. Twelve @entity1 with chronic type B @entity439 did not have operation, and all were alive at early follow-up. Mortality for @entity1 having acute type @entity439 requiring emergency operation was greater than that after elective repair of acute or chronic type @entity439 . Short-term survival for chronic type B @entity439 was similar whether the @entity1 was treated medically or surgically.

title: Repair of XXXX of the thoracic aorta: 12-year experience in a high-risk population.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity3617 :: ('MESH:D001991', 'Disease') :: ['bronchitis']

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertensive']

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['cerebrovascular disease']

entities_list: @entity886 :: ('MESH:C563178', 'Disease') :: ['aortic valve disease']

entities_list: @entity439 :: ('MESH:D000783', 'Disease') :: ['aneurysms', 'A aneurysms']

entities_list: @entity453 :: ('MESH:D003324', 'Disease') :: ['coronary artery disease']

entities_list: @entity1028 :: ('MESH:D017544', 'Disease') :: ['abdominal aortic aneurysm']

entities_list: @entity65 :: ('MESH:D002318', 'Disease') :: ['cardiovascular disease']

answer: @entity439 :: (MESH:D000783,Disease) :: ['aneurysms']


abstract: @entity281 has been described for the most part in adults. ORL and @entity1729 are encountered in @entity1 . In neonates, only @entity2024 have been reported. In their report, the authors describes the first cases of @entity281 due to @entity6729 in premature @entity1 with @entity649 . Three cases are described in which this bacteria has been isolated in bronchial secretions and in the culture of the nasotracheal tube. Clinical and biological features were not specific. Only orosomucoid serum level was increased. A favourable outcome was obtained by macrolides. Epidemiological survey permitted the isolation of @entity6729 in one of the nurse who had taken care of the neonates. Otherwise, these infections occurs in immunologically compromised hosts. @entity8855 appears most likely as an auspicious factor.

title: [ XXXX in neonatal pulmonary infectious pathology].

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'infants']

entities_list: @entity8855 :: ('MESH:D006819', 'Disease') :: ['Hyaline membrane disease']

entities_list: @entity649 :: ('MESH:D012128', 'Disease') :: ['respiratory distress syndrome']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['bronchopulmonary infections', 'Bronchopulmonary infections']

entities_list: @entity1729 :: ('MESH:D012141', 'Disease') :: ['upper respiratory tract infections']

entities_list: @entity2024 :: ('MESH:D003231', 'Disease') :: ['conjunctivitis']

entities_list: @entity6729 :: ('480', 'Species') :: ['Branhamella Catarrhalis']

answer: @entity6729 :: (480,Species) :: ['Branhamella catarrhalis']


abstract: BACKGROUND: The efficacy of @entity1499 ( @entity6822 ) varies in the treatment of @entity1569 . OBJECTIVE: We sought to identify an indicator from routine pretreatment tests to predict @entity6822 efficacy in the treatment of @entity1569 . METHODS: In a retrospective analysis of 77 psoriatic @entity1 , the correlation between @entity6822 efficacy and pretreatment routine test results was analyzed with Spearman correlation. The potential risks were further evaluated with a linear regression model. Receiver operating characteristic analysis was performed to examine the effectiveness of serum total @entity460 (tCa) to predict the effect of @entity6822 on @entity1569 . The highest Youden index was used to determine the cutoff point, with which the positive and negative predictive values were calculated. Synergistic effects of @entity6822 and @entity460 on keratinocyte growth and @entity1569 -like @entity19 model were also investigated. RESULTS: The pretreatment tCa level exhibited the closest association with @entity6822 efficacy. The relative @entity1569 improvement with tCa was 61.07% (95% confidence interval, 42.85-79.29; P  <  .001) and better improvements were observed in @entity1 with higher tCa (r  =  0.588; P  <  .002). @entity6822 inhibited keratinocyte growth, which was enhanced synergistically by @entity460 . In a @entity1569 -like @entity19 model, @entity6822 strongly inhibited epidermis proliferation in the high- @entity460 group. LIMITATIONS: One limitation of our study is the relatively small sample size. CONCLUSION: Pretreatment tCa level has the highest correlation with @entity6822 efficacy, which might be useful  in  predicting beneficial treatment results in @entity1569 . Larger studies are required to confirm our findings.

title: Can pretreatment serum @entity460 level predict the efficacy of XXXX in the treatment of severe @entity1569 ?

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity1569 :: ('MESH:D011565', 'Disease') :: ['psoriasis']

entities_list: @entity460 :: ('MESH:D002118', 'Chemical') :: ['calcium']

entities_list: @entity1499 :: ('MESH:D008727', 'Chemical') :: ['methotrexate']

answer: @entity1499 :: (MESH:D008727,Chemical) :: ['methotrexate']


abstract: BACKGROUND: The efficacy of @entity1499 ( @entity6822 ) varies in the treatment of @entity1569 . OBJECTIVE: We sought to identify an indicator from routine pretreatment tests to predict @entity6822 efficacy in the treatment of @entity1569 . METHODS: In a retrospective analysis of 77 psoriatic @entity1 , the correlation between @entity6822 efficacy and pretreatment routine test results was analyzed with Spearman correlation. The potential risks were further evaluated with a linear regression model. Receiver operating characteristic analysis was performed to examine the effectiveness of serum total @entity460 (tCa) to predict the effect of @entity6822 on @entity1569 . The highest Youden index was used to determine the cutoff point, with which the positive and negative predictive values were calculated. Synergistic effects of @entity6822 and @entity460 on keratinocyte growth and @entity1569 -like @entity19 model were also investigated. RESULTS: The pretreatment tCa level exhibited the closest association with @entity6822 efficacy. The relative @entity1569 improvement with tCa was 61.07% (95% confidence interval, 42.85-79.29; P  <  .001) and better improvements were observed in @entity1 with higher tCa (r  =  0.588; P  <  .002). @entity6822 inhibited keratinocyte growth, which was enhanced synergistically by @entity460 . In a @entity1569 -like @entity19 model, @entity6822 strongly inhibited epidermis proliferation in the high- @entity460 group. LIMITATIONS: One limitation of our study is the relatively small sample size. CONCLUSION: Pretreatment tCa level has the highest correlation with @entity6822 efficacy, which might be useful  in  predicting beneficial treatment results in @entity1569 . Larger studies are required to confirm our findings.

title: Can pretreatment serum @entity460 level predict the efficacy of @entity1499 in the treatment of severe XXXX ?

answer: @entity1569 :: (MESH:D011565,Disease) :: ['plaque psoriasis']


abstract: BACKGROUND: The efficacy of @entity1499 ( @entity6822 ) varies in the treatment of @entity1569 . OBJECTIVE: We sought to identify an indicator from routine pretreatment tests to predict @entity6822 efficacy in the treatment of @entity1569 . METHODS: In a retrospective analysis of 77 psoriatic @entity1 , the correlation between @entity6822 efficacy and pretreatment routine test results was analyzed with Spearman correlation. The potential risks were further evaluated with a linear regression model. Receiver operating characteristic analysis was performed to examine the effectiveness of serum total @entity460 (tCa) to predict the effect of @entity6822 on @entity1569 . The highest Youden index was used to determine the cutoff point, with which the positive and negative predictive values were calculated. Synergistic effects of @entity6822 and @entity460 on keratinocyte growth and @entity1569 -like @entity19 model were also investigated. RESULTS: The pretreatment tCa level exhibited the closest association with @entity6822 efficacy. The relative @entity1569 improvement with tCa was 61.07% (95% confidence interval, 42.85-79.29; P  <  .001) and better improvements were observed in @entity1 with higher tCa (r  =  0.588; P  <  .002). @entity6822 inhibited keratinocyte growth, which was enhanced synergistically by @entity460 . In a @entity1569 -like @entity19 model, @entity6822 strongly inhibited epidermis proliferation in the high- @entity460 group. LIMITATIONS: One limitation of our study is the relatively small sample size. CONCLUSION: Pretreatment tCa level has the highest correlation with @entity6822 efficacy, which might be useful  in  predicting beneficial treatment results in @entity1569 . Larger studies are required to confirm our findings.

title: Can pretreatment serum XXXX level predict the efficacy of @entity1499 in the treatment of severe @entity1569 ?

answer: @entity460 :: (MESH:D002118,Chemical) :: ['calcium']


abstract: AIMS: Current smokers in the general population have a lower 2 h plasma @entity413 after an oral @entity413 tolerance test (OGTT) and a higher HbA1c than non-smokers, but the relationships between OGTT/HbA1c and smoking status have not been addressed in pregnancy. We analysed glycaemic measurements in @entity1 with @entity6 in relation to smoking status. METHODS: We performed a review of the prospectively collected database of the @entity6 . We included @entity1 with @entity6 and a singleton pregnancy who delivered between 1986 and 2006. Bivariate and multivariate analyses were used to evaluate @entity1 characteristics in relation to smoking status. RESULTS: A total of 2361 @entity1 met the inclusion criteria: 556 (23.5%) were active smokers, 266 (11.3%) quit during pregnancy and 1539 (65.2%) were non-smokers. Most baseline characteristics were similar across groups. Diagnostic OGTT was performed at a gestational age of [median (25th, 75(th) centiles)] 29 weeks (26, 33). @entity1 who smoked at the beginning of pregnancy had a higher 1-h plasma @entity413 than non-smokers [11.8 (11, 12.7), 11.6 (11, 12.6) and 11.5 (10.8, 12.5) mmol/l, for active smokers, those who quit during pregnancy and non-smokers, respectively, P < 0.001] and a lower 3-h plasma @entity413 [7.3 (5.9, 8.4), 7.6 (6.4, 8.7) and 8.0 (6.8, 9.0) mmol/l, respectively, P < 0.001]. HbA1c was higher in @entity1 who smoked at the beginning of pregnancy. Multiple regression analysis confirmed the independent association of smoking status with HbA1c and OGTT plasma @entity413 . CONCLUSIONS: In @entity1 with @entity6 who smoke at the beginning of pregnancy, the shape of the OGTT is consistent with accelerated @entity413 absorption, and @entity4051 c is higher than expected for glycaemic values.

title: Smoking affects the oral @entity413 tolerance test profile and the relationship between @entity413 and XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patient', 'Women']

entities_list: @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['gestational diabetes mellitus', 'diabetes and pregnancy clinic']

answer: @entity6 :: (MESH:D003920,Disease) :: ['HbA1c in gestational diabetes mellitus']


abstract: AIMS: Current smokers in the general population have a lower 2 h plasma @entity413 after an oral @entity413 tolerance test (OGTT) and a higher HbA1c than non-smokers, but the relationships between OGTT/HbA1c and smoking status have not been addressed in pregnancy. We analysed glycaemic measurements in @entity1 with @entity6 in relation to smoking status. METHODS: We performed a review of the prospectively collected database of the @entity6 . We included @entity1 with @entity6 and a singleton pregnancy who delivered between 1986 and 2006. Bivariate and multivariate analyses were used to evaluate @entity1 characteristics in relation to smoking status. RESULTS: A total of 2361 @entity1 met the inclusion criteria: 556 (23.5%) were active smokers, 266 (11.3%) quit during pregnancy and 1539 (65.2%) were non-smokers. Most baseline characteristics were similar across groups. Diagnostic OGTT was performed at a gestational age of [median (25th, 75(th) centiles)] 29 weeks (26, 33). @entity1 who smoked at the beginning of pregnancy had a higher 1-h plasma @entity413 than non-smokers [11.8 (11, 12.7), 11.6 (11, 12.6) and 11.5 (10.8, 12.5) mmol/l, for active smokers, those who quit during pregnancy and non-smokers, respectively, P < 0.001] and a lower 3-h plasma @entity413 [7.3 (5.9, 8.4), 7.6 (6.4, 8.7) and 8.0 (6.8, 9.0) mmol/l, respectively, P < 0.001]. HbA1c was higher in @entity1 who smoked at the beginning of pregnancy. Multiple regression analysis confirmed the independent association of smoking status with HbA1c and OGTT plasma @entity413 . CONCLUSIONS: In @entity1 with @entity6 who smoke at the beginning of pregnancy, the shape of the OGTT is consistent with accelerated @entity413 absorption, and @entity4051 c is higher than expected for glycaemic values.

title: Smoking affects the oral XXXX tolerance test profile and the relationship between @entity413 and @entity6 .

answer: @entity413 :: (MESH:D005947,Chemical) :: ['glucose']


abstract: AIMS: Current smokers in the general population have a lower 2 h plasma @entity413 after an oral @entity413 tolerance test (OGTT) and a higher HbA1c than non-smokers, but the relationships between OGTT/HbA1c and smoking status have not been addressed in pregnancy. We analysed glycaemic measurements in @entity1 with @entity6 in relation to smoking status. METHODS: We performed a review of the prospectively collected database of the @entity6 . We included @entity1 with @entity6 and a singleton pregnancy who delivered between 1986 and 2006. Bivariate and multivariate analyses were used to evaluate @entity1 characteristics in relation to smoking status. RESULTS: A total of 2361 @entity1 met the inclusion criteria: 556 (23.5%) were active smokers, 266 (11.3%) quit during pregnancy and 1539 (65.2%) were non-smokers. Most baseline characteristics were similar across groups. Diagnostic OGTT was performed at a gestational age of [median (25th, 75(th) centiles)] 29 weeks (26, 33). @entity1 who smoked at the beginning of pregnancy had a higher 1-h plasma @entity413 than non-smokers [11.8 (11, 12.7), 11.6 (11, 12.6) and 11.5 (10.8, 12.5) mmol/l, for active smokers, those who quit during pregnancy and non-smokers, respectively, P < 0.001] and a lower 3-h plasma @entity413 [7.3 (5.9, 8.4), 7.6 (6.4, 8.7) and 8.0 (6.8, 9.0) mmol/l, respectively, P < 0.001]. HbA1c was higher in @entity1 who smoked at the beginning of pregnancy. Multiple regression analysis confirmed the independent association of smoking status with HbA1c and OGTT plasma @entity413 . CONCLUSIONS: In @entity1 with @entity6 who smoke at the beginning of pregnancy, the shape of the OGTT is consistent with accelerated @entity413 absorption, and @entity4051 c is higher than expected for glycaemic values.

title: Smoking affects the oral @entity413 tolerance test profile and the relationship between XXXX and @entity6 .

answer: @entity413 :: (MESH:D005947,Chemical) :: ['glucose']


abstract: BACKGROUND: Controversies on how to treat upper @entity418 have existed for several decades. With the application of minimally invasive techniques, surgical treatment to upper @entity418 tends to show more advantages and attract more @entity1 . Up to now, most hospitals adopted the @entity18274 ( @entity18274 ) as the way of minimally invasive surgery for upper @entity418 . But @entity18274 to treat upper @entity418 has its drawbacks, such as demanding certain pulmonary function and severe @entity86 . In 2011, we developed the gasless laparoscopic transhiatal esophagectomy (LTE) to treat upper @entity418 , which showed some advantages. The aim of this article was to compare LTE with @entity18274 in treating @entity418 and assess the value of LTE. METHODS: From 2009 to 2014, esophagectomy has been performed by the introduction of minimally invasive surgery in a total of 83 @entity1 with @entity418 . Among these @entity1 , LTE was performed in 27 cases (Group 1), while @entity18274 was performed in the other 56 (Group 2). Neoadjuvant chemotherapy was done in @entity1 of Group 1. RESULTS: There were no operation-related deaths and conversion to open procedure. There was no significant difference in postoperative complications, ventilation time, ICU stay, hospital stay, and @entity834 rates between the two groups. But LTE was associated with shorter operative time and less intraoperative @entity190 . In Group 2, 21 (37.5  %) @entity1 had @entity260 , while in Group 1, there were 6 (22.2  %) @entity1 having @entity358 at least one time. Results of 24-h pH monitoring and manometry showed that postoperative laryngo-pharyngeal reflux (PLPR) was more severe in Group 2 @entity1 than in Group 1; for Group 1, PLPR mainly occurred on sleep stage, while for Group 2, PLPR might exist all the day with short intervals and last longer at night. The median overall survival was 27.2  months after @entity18274 and 30.8  months after LTE (P  =  0.962). There was no significant difference in survival at 2, 3 and 4  years between the two groups. CONCLUSIONS: Compared with @entity18274 , LTE is a more minimally invasive approach to effectively treat @entity1 with upper @entity418 . Laryngo-pharyngeal reflux after LTE was less severe than that after @entity18274 , which might lower incidence of @entity358 . For the elderly @entity1 , LTE seems more suitable.

title: Pros and cons of the gasless laparoscopic transhiatal esophagectomy for upper XXXX .

entities_list: @entity834 :: ('MESH:D057868', 'Disease') :: ['anastomotic leak']

entities_list: @entity190 :: ('MESH:D006473', 'Disease') :: ['blood loss']

entities_list: @entity260 :: ('MESH:D011183', 'Disease') :: ['postoperative pulmonary complications']

entities_list: @entity18274 :: ('MESH:D009100', 'Disease') :: ['combined thoracoscopic and laparoscopic esophagectomy', 'CTLE']

entities_list: @entity358 :: ('MESH:D008171', 'Disease') :: ['pulmonary complications']

entities_list: @entity86 :: ('MESH:D019106', 'Disease') :: ['postoperative regurgitation']

entities_list: @entity418 :: ('MESH:D004938', 'Disease') :: ['upper thoracic or cervical esophageal carcinoma', 'esophageal carcinoma']

answer: @entity418 :: (MESH:D004938,Disease) :: ['esophageal carcinoma']


abstract: UNASSIGNED: Locally advanced @entity420 is treated with radiochemotherapy (RCT) before surgery. The response to RCT is heterogeneous and consensus regarding reliable predictors is lacking. Since the @entity3963 pathway is implicated in radioprotection, we examined pretreatment biopsies from 52 @entity1 by immunohistochemistry for phosphorylated @entity3963 (pERK). Immunostaining for pERK was considerably enhanced by use of alkaline demasking. Nuclear staining occurred in both @entity5 cells and stromal cells. Blind-coded sections were scored by 2 independent investigators. In @entity1 showing no @entity41 after RCT ( @entity17198 ), staining for pERK in @entity5 , but not stromal, cell nuclei was significantly weaker than in @entity1 showing a poor RCT response ( @entity17198 vs @entity55053 : p = 0.0001). Nuclear staining for pERK predicted poor responders, as illustrated by receiver operating characteristic curves with an area under curve of 0.86 (p = 0.0007) and also predicted downstaging (area under curve: 0.76; p = 0.01). A number of controls documented the specificity of the optimized staining method and results were confirmed with another pERK antibody. Thus, staining for pERK in @entity5 cell nuclei can predict the response to RCT and may help spare poor responders this treatment. These results also raise the question whether inhibitors of @entity3963 activation may serve as response modifiers of RCT.

title: Phospho-ERK1/2 levels in @entity5 cell nuclei predict responsiveness to radiochemotherapy of XXXX .

entities_list: @entity41 :: ('MESH:D018365', 'Disease') :: ['residual tumor']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer']

entities_list: @entity420 :: ('MESH:D000230', 'Disease') :: ['rectal adenocarcinoma']

answer: @entity420 :: (MESH:D000230,Disease) :: ['rectal adenocarcinoma']


abstract: UNASSIGNED: Locally advanced @entity420 is treated with radiochemotherapy (RCT) before surgery. The response to RCT is heterogeneous and consensus regarding reliable predictors is lacking. Since the @entity3963 pathway is implicated in radioprotection, we examined pretreatment biopsies from 52 @entity1 by immunohistochemistry for phosphorylated @entity3963 (pERK). Immunostaining for pERK was considerably enhanced by use of alkaline demasking. Nuclear staining occurred in both @entity5 cells and stromal cells. Blind-coded sections were scored by 2 independent investigators. In @entity1 showing no @entity41 after RCT ( @entity17198 ), staining for pERK in @entity5 , but not stromal, cell nuclei was significantly weaker than in @entity1 showing a poor RCT response ( @entity17198 vs @entity55053 : p = 0.0001). Nuclear staining for pERK predicted poor responders, as illustrated by receiver operating characteristic curves with an area under curve of 0.86 (p = 0.0007) and also predicted downstaging (area under curve: 0.76; p = 0.01). A number of controls documented the specificity of the optimized staining method and results were confirmed with another pERK antibody. Thus, staining for pERK in @entity5 cell nuclei can predict the response to RCT and may help spare poor responders this treatment. These results also raise the question whether inhibitors of @entity3963 activation may serve as response modifiers of RCT.

title: Phospho-ERK1/2 levels in XXXX cell nuclei predict responsiveness to radiochemotherapy of @entity420 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

answer: @entity5 :: (MESH:D009369,Disease) :: ['cancer']


abstract: The presence of a cervical cerclage at the time of preterm premature @entity397 potentially complicates this already difficult management problem. An analysis of 44 @entity1 presenting with preterm premature @entity397 was conducted. Twelve @entity1 were immediately delivered because of fetal distress, labor, or mature fetal pulmonary studies. Thirty-two @entity1 entered an expectant management protocol. The cervical cerclage was removed on admission to the study. These @entity1 were compared with 32 matched control subjects. There appears to be no difference in neonatal or maternal outcome between the study and control groups. The latency period from premature @entity397 until delivery was not affected by the presence or removal of the cerclage. There was no difference in infectious complications. These data suggest that the presence of a cervical cerclage at the time of preterm premature @entity397 does not increase the risk of delivery or infectious morbidity as long as the cerclage is removed early in the management protocol.

title: The role of cervical cerclage in the management of preterm premature XXXX .

entities_list: @entity397 :: ('MESH:D012421', 'Disease') :: ['rupture of the membranes', 'rupture of the membranes and cervical cerclage']

answer: @entity397 :: (MESH:D012421,Disease) :: ['rupture of the membranes']


abstract: We studied whether the biomechanical properties of brain play an important role in the development of early ischemic @entity2657 in @entity468 with @entity2500 . Brain tissue pressure, tissue compliance, and tissue resistance were measured from the gray matter in the core and the periphery of the middle cerebral artery territory for 6 hours after occlusion. Regional cerebral blood flow and water content were also measured from the same areas. Ventricular fluid pressure was recorded. Tissue pressure rose gradually in the core, where flow was 6 ml/100 g/min, over 4 hours and then stabilized. The pressure gradient measured between @entity4 tissue and ventricular fluid was 5.3 mm Hg. Tissue resistance increased 1 hour after occlusion when water content increased to 10 mg/g. Later, when water content increased by 40 mg/g, tissue resistance decreased and tissue compliance increased significantly. In the periphery, where flow was 17.6 ml/100 g/min, tissue pressure rose slightly while tissue compliance and tissue resistance did not change within 6 hours. Our data indicate that as @entity63 progresses, @entity4 fluid accumulates in highly compliant brain parenchyma, then migrates through highly conductive tissue into the cerebrospinal fluid spaces, driven by the hydrostatic pressure gradient between the @entity4 tissue and the cerebrospinal fluid.

title: Biomechanics of XXXX in acute cerebral ischemia in @entity468 .

entities_list: @entity2657 :: ('MESH:D001929', 'Disease') :: ['brain edema']

entities_list: @entity63 :: ('MESH:D007511', 'Disease') :: ['ischemic injury']

entities_list: @entity2500 :: ('MESH:D020244', 'Disease') :: ['middle cerebral artery occlusion']

entities_list: @entity4 :: ('MESH:D004487', 'Disease') :: ['edematous', 'edema']

answer: @entity2657 :: (MESH:D001929,Disease) :: ['brain edema']


abstract: We studied whether the biomechanical properties of brain play an important role in the development of early ischemic @entity2657 in @entity468 with @entity2500 . Brain tissue pressure, tissue compliance, and tissue resistance were measured from the gray matter in the core and the periphery of the middle cerebral artery territory for 6 hours after occlusion. Regional cerebral blood flow and water content were also measured from the same areas. Ventricular fluid pressure was recorded. Tissue pressure rose gradually in the core, where flow was 6 ml/100 g/min, over 4 hours and then stabilized. The pressure gradient measured between @entity4 tissue and ventricular fluid was 5.3 mm Hg. Tissue resistance increased 1 hour after occlusion when water content increased to 10 mg/g. Later, when water content increased by 40 mg/g, tissue resistance decreased and tissue compliance increased significantly. In the periphery, where flow was 17.6 ml/100 g/min, tissue pressure rose slightly while tissue compliance and tissue resistance did not change within 6 hours. Our data indicate that as @entity63 progresses, @entity4 fluid accumulates in highly compliant brain parenchyma, then migrates through highly conductive tissue into the cerebrospinal fluid spaces, driven by the hydrostatic pressure gradient between the @entity4 tissue and the cerebrospinal fluid.

title: Biomechanics of @entity2657 in acute cerebral ischemia in XXXX .

answer: @entity468 :: (9685,Species) :: ['cats']


abstract: Twenty-four consecutive @entity1 with @entity174 nonunion in the metaphyseal-epiphyseal areas of long bones were surgically treated. Average time from injury to treatment of the nonunion was 10 months, and average follow-up time after surgical treatment was 29 months. Eight @entity1 with infected nonunions had initial debridement procedures; three of these @entity1 then had placement of external fixators and bone grafting. The remaining five @entity1 and 13 others were then treated by open reduction and internal fixation alone or with the addition of autogenous cancellous bone grafting. Single or double plates and screws were used. Arthrolysis, joint manipulation, and intensive postsurgical exercises were considered necessary to regain joint function. One @entity1 underwent a hemiarthroplasty, and two others underwent arthrodesis as the initial nonunion treatment. Twenty of the 21 @entity1 not treated by arthrodesis or arthroplasty healed their @entity174 in an average time of 7 months. Fifty-two percent of the @entity1 achieved good or excellent range of motion (ROM) of the contiguous joint, with 70% of the @entity1 reporting no @entity158 in this joint. These @entity174 have excellent intrinsic healing capability because they occur in anatomical regions with a normally abundant circulation. We recommend stable fixation, with the need for bone grafting only in defect nonunions, together with intra- and postoperative joint mobilization to obtain a satisfactory functional end result.

title: Treatment of nonunion of XXXX in the epiphyseal-metaphyseal region of long bones.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity174 :: ('MESH:D050723', 'Disease') :: ['fractures', 'fracture']

answer: @entity174 :: (MESH:D050723,Disease) :: ['fractures']


abstract: UNASSIGNED: Recently, rapid advances in bioinformatics analysis have expanded our understanding of the transcriptome to a genome-wide level. miRNA-mRNA-lncRNA interactions have been shown to play critical regulatory role in @entity5 biology. In this study, we discussed the use of an integrated systematic approach to explore new facets of the @entity2931 receptor (ER)-regulated transcriptome. The identification of RNAs that are related to the expression status of the ER may be useful in clinical therapy and prognosis. We used a network modelling strategy. First, microarray expression profiling of mRNA, lncRNA and miRNA was performed in MCF-7 (ER-positive) and MDA-MB-231 cells (ER- negative). A co-expression network was then built using co-expression relationships of the differentially expressed mRNAs and lncRNAs. Finally, the selected miRNA-mRNA network was added to the network. The key miRNA-mRNA-lncRNA interaction can be inferred from the network. The mRNA and non-coding RNA expression profiles of the cells with different ER phenotypes were distinct. Among the aberrantly expressed miRNAs, the expression levels of @entity34947 -3p, miR-19b-3p and miR-130a-3p were much lower in the MCF-7 cells, whereas that of @entity20478 -3p was much higher. In a cluster of @entity10014 , the expression levels of six of seven miRNAs were lower in the MCF-7 cells, in addition to @entity22075 in the @entity20591 -363 cluster. However, the levels of all the miRNAs in the @entity20591 -25 cluster were higher in the MCF-7 cells. In the co-expression networking, @entity5933 and @entity73296 gene which is involved in the immune response and @entity3 , respectively, had a stronger correlation with ER. Among the aberrantly expressed lncRNAs, lncRNA- @entity8332 was highly expressed in the MCF-7 cells. A statistical analysis revealed that there was a co-expression relationship between @entity1782 and lncRNA- @entity8332 . In addition, @entity34947 and lncRNA- @entity8332 are both located on the @entity1 chromosome 13q. We speculate that @entity34947 might be co-expressed with lncRNA- @entity8332 to co-regulate the expression of @entity1782 , which influences the occurrence and development of @entity0 cells with different levels of ER expression. Our findings reveal that the status of ER is mainly due to the differences in the mRNA and ncRNA profile between the @entity0 cell lines, and highlight the importance of studying the miRNA-mRNA-lncRNA interactions to completely illustrate the intricate transcriptome.

title: Analysis of the miRNA-mRNA-lncRNA networks in ER+ and ER- XXXX cell lines.

entities_list: @entity2931 :: ('CHEBI:50114', 'Chemical') :: ['oestrogen']

entities_list: @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis']

answer: @entity0 :: (MESH:D001943,Disease) :: ['breast cancer']


abstract: At glutamatergic synapses, @entity143 receptors (NMDARs) are localized with other ionotropic @entity2227 receptors [ @entity140 receptors (AMPARs) and @entity4176 receptors] and with metabotropic @entity2227 receptors. Targeting the necessary number of NMDARs to the proper sites at synapses is critical for normal glutamatergic neurotransmission and synaptic plasticity. Additional diversity of NMDAR responses arises from the complexity of subunit composition and variations in localization. Thus, the mechanisms of NMDAR trafficking and targeting must address the complex needs of neurons. For example, NMDARs must be transported to different subcellular sites because some receptors are localized to synaptic sites (pre- and postsynaptic) while others are localized extrasynaptically [1   4]. NMDAR subunit expression differs as a function of brain region and developmental age [5   7]. Subunit composition may determine subcellular localization, i.e., in adults, @entity11588 -containing receptors are enriched at synapses while extrasynaptic receptors are predominantly @entity13069 -containing complexes [1,2,4]. Furthermore, evidence indicates the incorporation of more than one type of NR2 subunit in each complex (tri-heteromeric @entity6806 /NR2X/NR2Y) such as @entity6806 / @entity11588 / @entity13069 receptors in hippocampal neuron synapses, @entity6806 / @entity11588 / @entity21413 in cerebellar granule cell synapses, and @entity6806 / @entity13069 / @entity21412 in substantia nigra dopaminergic neurons [8]. Finally, different NMDARs may be expressed at different synapses within the same neuron [4]. Thus, the mechanisms of NMDAR trafficking must be varied and well regulated to meet the needs of neurons.

title: Trafficking and Targeting of XXXX Receptors

entities_list: @entity2227 :: ('CHEBI:29987', 'Chemical') :: ['glutamate']

answer: @entity143 :: (CHEBI:6121,Chemical) :: ['NMDA']


abstract: BACKGROUND: Programs to change health behaviours have been identified as one way to reduce health inequalities experienced by disadvantaged groups. The objective of this study was to examine the effectiveness of a behaviour change programme to increase walking and reduce sedentary behaviour of adults with @entity717 . METHODS: We used a cluster randomised controlled design and recruited @entity1 over 18  years old and not regularly involved in physical activity from @entity717 community-based organisations. Assessments were carried out blind to allocation. Clusters of @entity1 were randomly allocated to the Walk Well program or a 12-week waiting list control. Walk Well consisted of three face-to-face physical activity consultations incorporating behaviour change techniques, written resources for @entity1 and carers, and an individualised, structured walking programme. The primary outcome measured with accelerometers was change in mean step count per day between baseline and 12  weeks. Secondary outcomes included percentage time per day sedentary and in moderate-vigorous physical activity (MVPA), body mass index (BMI), and subjective well being. RESULTS: One hundred two @entity1 in 50 clusters were randomised. 82 (80.4  %) @entity1 completed the primary outcome. 66.7  % of @entity1 lived in the most deprived quintile on the Scottish Index of Multiple Deprivation. At baseline, @entity1 walked 4780 (standard deviation 2432) steps per day, spent 65.5  % (standard deviation 10.9) of time sedentary and 59  % percent had a body mass in the @entity28 range. After the walking programme, the difference between mean counts of the Walk Well and control group was 69.5 steps per day [95  % confidence interval (CI) -1054 to 1193.3]. There were no significant between group differences in percentage time sedentary 1.6  % (95  % CI -2.984 to 6.102), percentage time in MVPA 0.3  % (95  % CI -0.7 to 1.3), BMI -0.2  kg/m(2) (95  % CI -0.8 to 0.4) or subjective well-being 0.3 (95  % CI -0.9 to 1.5). CONCLUSIONS: This is the first published trial of a walking program for adults with @entity717 . Positively changing physical activity and sedentary behaviours may require more intensive programmes or upstream approaches to address the multiple social disadvantages experienced by adults with @entity717 . Since @entity1 spent the majority of their time sedentary, home-based programmes to reduce sitting time may be a viable health improvement approach. TRIAL REGISTRATION: Current Controlled Trials ISRCTN50494254.

title: Effectiveness of a walking programme to support adults with XXXX to increase physical activity: walk well cluster-randomised controlled trial.

entities_list: @entity1 :: ('9606', 'Species') :: ['participants']

entities_list: @entity717 :: ('MESH:D009069', 'Disease') :: ['intellectual disabilities']

entities_list: @entity28 :: ('MESH:D009765', 'Disease') :: ['obesity']

answer: @entity717 :: (MESH:D009069,Disease) :: ['intellectual disabilities']